Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: Is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?

Histopathology

Volumn 49, Issue 6, 2006, Pages 576-581

  Liegl, B ^a   Leithner, A ^a   Bauernhofer, T ^a   Windhager, R ^a   Guelly, C ^a   Regauer, S ^a   Beham, A ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Fibromatosis; Gleevec; PDGFR ; PDGFR

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA ANTIBODY; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADULT; ARTICLE; DESMOID TUMOR; DNA SEQUENCE; DRUG MECHANISM; EXON; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR RECURRENCE;

ADULT; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENZYME INHIBITORS; FEMALE; FIBROMATOSIS, ABDOMINAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33845517247     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02562.x     Document Type: Article

References (38)

1. Weiss SW, Goldblum JR. Fibromatosis. In Enzinger FW, Weiss SW eds. Soft tissue tumors, 4th edn. St Louis: C.V. Mosby 2001; 309-346.
2. Gardner EJ. Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal polyps, osteomas, fibromas and epidermal cysts. Am. J. Hum. Genet. 1962; 14; 376-390.
3. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am. J. Clin. Pathol. 1982; 77; 674-680.
4. Hamilton SR, Aaltonen LA. Tumours of the digestive system. Lyon: IARC Press 2000.
5. Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum. Pathol. 1996; 27; 939-943.
6. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J. Clin. Oncol. 1999; 17; 158-167.
7. Kulaylat MN, Karakousis CP, Keaney CM, McCorvey D, Bem J, Ambrus JL Sr. Desmoid tumour: a pleomorphic lesion. Eur. J. Surg. Oncol. 1999; 25; 487-497.
8. Belliveau P, Graham AM. Mesenteric desmoid tumor in Gardner's syndrome treated by sulindac. Dis. Colon Rectum 1984; 27; 53-54.
9. Klein WA, Miller HH, Anderson M, DeCosse JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 1987; 60; 2863-2868.
10. Waddell WR, Gerner RE, Reich MP. Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J. Surg. Oncol. 1983; 22; 197-211.
11. Waddell WR, Kirsc WM. Testolactone, sulindac, warfarin, and vitamin K for unresectable desmoid tumors. Am. J. Surg. 1991; 161; 416-421.
12. Bauernhofer T, Stoger H, Schmid M et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996; 77; 1061-1065.
13. Tonelli F, Valanzano R, Brandi ML. Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery 1994; 115; 473-479.
14. Fernberg J, Brosjo O, Larsson O, Soderlund V, Strander H. Interferon-induced remission in aggressive fibromatosis of the lower extremity. Acta Oncol. 1999; 38; 971-972.
15. Lotfi AM, Dozios RR, Gordon H. Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int. J. Colorectal Dis. 1989; 4; 30-36.
16. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann. Surg. 1989; 210; 765-769.
17. Waddell WR. Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3,5-adenosine monophosphate. Ann. Surg. 1975; 85; 475-477.
18. Schnitzler M, Cohen Z, Blackstein M. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis. Colon Rectum 1997; 40; 798-801.
19. Carroll M, Ohno-Jones S, Tamura S. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of dells expressing BCR-Abl, TEL-Abl, and TEL-PDGFR fusion proteins. Blood 1997; 90; 4947-4952.
20. Buchdunger E, Cioffi CL, Law N. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295; 139-145.
21. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347; 472-480.
22. Mace J, Sybil Biermann J, Sondak V et al. Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95; 2373-2379.
23. Leithner A, Gapp M, Radl R et al. Immunohistochemical analysis of desmoid tumours. J. Clin. Pathol. 2005; 58; 1152-1156.
24. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum. Pathol. 2005; 36; 242-249.
25. Sihto H, Sarlomo-Rikala M, Tynninen O et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J. Clin. Oncol. 2005; 23; 49-57.
26. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002; 1; 493-502.
27. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344; 1031-1037.
28. Rubin BP, Schuetze SM, Eary JF. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 2002; 20; 3586-3591.
29. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344; 1052-1056.
30. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 1998; 11; 728-734.
31. Heinrich MC, Blanke CD, Druker BJ. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002; 20; 1692-1703.
32. Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708-710.
33. Miettinen M. Are desmoid tumors kit positive? Am. J. Surg. Pathol. 2001; 25; 549-550.
34. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am. J. Clin. Pathol. 2002; 117; 188-193.
35. Lindblom P, Gerhardt H, Liebner S et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003; 17; 1835-1840.
36. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3; 439-443.
37. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin. Oncol. 2004; 31 (2 Suppl. 6); 18-23.
38. Kindler T, Breitenbuecher F, Marx A et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103; 3644-3654.